SAVA
Cassava Sciences, Inc.
$1.30
-4.41%
2026-05-08
About Cassava Sciences, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Key Fundamentals
Forward P/E
-1.34
EPS (TTM)
$-2.22
ROE
-85.4%
Profit Margin
0.0%
Price/Book
1.41
Beta
-0.84
Market Cap
$115.0M
Avg Volume (10D)
728K
Recent Breakout Signals
No recent breakout signals detected for SAVA.
Recent Price Range (60 Days)
60D High
$2.49
60D Low
$1.27
Avg Volume
522K
Latest Close
$1.30
Get breakout alerts for SAVA
Sign up for Breakout Scanner to receive daily notifications when SAVA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Cassava Sciences, Inc. (SAVA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SAVA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SAVA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.